Background PD-1 and PD-L1 inhibitors are active in metastatic urothelial carcinoma, but
positive randomised data supporting their use as a first-line treatment are lacking. In this study …

Results Sixty-three patients were randomly assigned to docetaxel (n= 41) or cabazitaxel (n=
22); 44.4% received prior potent androgen receptor–targeted therapy. Overall, 35 patients (…

Lamellarin D (LAM-D) is a marine alkaloid endowed with potent cytotoxic activities against
various tumor cells, in particular human prostate cancer cells and leukemia cells. Its cytotoxic …

Background: Inaccurate risk classification and the burden of unnecessary biopsies are a
challenge due to the limited ability of current risk assessment tools and modalities to diagnose …

Purpose Immune checkpoint programmed death-ligand 1 inhibitor therapy has shown
response in metastatic muscle invasive bladder cancer (MIBC). We evaluated the safety and …

Background Novel hormonal agents (NHAs) such as abiraterone acetate (ABI) and
enzalutamide (ENZ) are frequently used in metastatic castration-resistant prostate cancer (mCRPC). …

Background For Canadian men, prostate cancer (PCa) is the most common cancer and the
3rd leading cause of cancer mortality. Men dying of PCa do so after failing castration. The …

Methods Data were collected on mRCC patients using the prospective Canadian Kidney
Cancer Information System (CKCis) database from January 2011 to November 2015. Statistical …

Background: Androgen deprivation therapy (ADT) is a cornerstone of treatment for
advanced prostate cancer (PCa); however, it accelerates the loss of bone mineral density (BMD), …

Background: The role of chemotherapy in metastatic esophageal carcinoma (MEC) remains
a matter of debate. The aim of this retrospective study was to analyze the survival impact of …